Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 1Phase 1/2 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1FED 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4Gastrointestinal 3Other hematologic neoplasm 2Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1CNS 1Breast 1

Conditions

Uveal Melanoma 3Melanoma 2Ovarian Neoplasms 1Neoplasm Metastasis 1Glioma 1Carcinoma, Hepatocellular 1Carcinoma 1

Interventions

pembrolizumab 100Nivolumab 69Cyclophosphamide 67Ipilimumab 66fludarabine 34aldesleukin 29fludarabine phosphate 28Vemurafenib 28Interleukin-2 26trametinib 20Biopsy 20dabrafenib 17Radiotherapy 16Temozolomide 15Cisplatin 15Magnetic Resonance Spectroscopy 14Gemcitabine 14Filgrastim 14atezolizumab 13Specimen Handling 13Carboplatin 13CTLA-4 Antigen 13spartalizumab 12romidepsin 12Paclitaxel 12Bortezomib 11poly ICLC 10cobimetinib 10Peripheral Blood Stem Cell Transplantation 10Oxaliplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × ADI PEG20 × Dermatologic × Clear all
NCT03922880 2025-05-15

Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
9 enrolled
Dermatologic

Uveal Melanoma

NCT02029690 2020-09-25

TRAP

Polaris Group

Phase 1 Terminated
85 enrolled
CNSDermatologicGastrointestinal

Uveal Melanoma, Carcinoma, Glioma, Carcinoma, Hepatocellular

NCT01665183 2016-02-25

Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma

Polaris Group

Phase 1 Completed
8 enrolled
DermatologicGynecologic

Uveal Melanoma, Melanoma, Ovarian Neoplasms

NCT00029900 2015-03-25

ADI-PEG in Patients With Metastatic Melanoma

FDA Office of Orphan Products Development

Phase 1 Completed
15 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡